Troy Cox, Michael Pellini
Foundation Medicine announced that it has appointed Troy Cox as CEO to succeed Michael Pellini, who has been appointed as chairman of the board of directors. Pellini replaces Alexis Borisy, who will continue to serve on the board. Cox joins Foundation Medicine from Roche-Genentech, where he led one of the largest oncology portfolios in the US. Before joining Genentech, he held leadership positions at UCB BioPharma, Sanofi-Aventis, and Schering-Plough.
The National Institutes of Health announced today that Philip Bourne will be leaving his post as associate director for data science effective April 30, 2017. Bourne joined the NIH in 2014 to lead the Big Data to Knowledge program. He will join the University of Virginia, Charlottesville as Stephenson Chair of data science, director of the Data Science Institute, and professor in the Department of Biomedical Engineering.
Illumina has hired Garret Hampton as executive vice president of clinical genomics, effective Jan. 9, 2017. Hampton will be responsible for Illumina's clinical genomics group, leading the reproductive and genetic health, oncology, and regulatory and medical affairs business units. He will also oversee CLIA labs and the chief medical officers organization. Previously, Hampton served as global head of oncology biomarker development and companion diagnostics at Genentech. He also co-led the Roche personalized medicine R&D initiative and chaired the Roche/Foundation Medicine joint R&D committee. In addition, he has held scientific and management roles at Celgene, the Genomics Institute of the Novartis Research Foundation, and the University of California, San Diego.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.